Clinical Trial Update: Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety and efficacy of Treanda (bendamustine HCl) in patients with indolent non-Hodgkin lymphoma refractory to rituximab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Treanda (Bendamustine)

Snippet

Sponsor: Cephalon | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED